Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$37.39 USD
+0.51 (1.38%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $37.38 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Apellis Pharmaceuticals, Inc. [APLS]
Reports for Purchase
Showing records 141 - 160 ( 293 total )
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FDA Tees Up A November PDUFA for Pegcetacoplan in GA
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ASGCT 2022 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Eye Can?t Wait To See What Happens With The Pegcetacoplan Filing
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Commercial Biotech Preview: Let''s Get It Over With
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Year of the Kidney: A Deep Dive Primer On Glomerular Disorders
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Slight Improvement at 18 Months, if One Waits that Long
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department